Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17195961 | 0.82 | GMNN (0.31) | — | |
| SCHEMBL8978731 | 0.70 | — | — | |
| SCHEMBL17878214 | 0.62 | NQO1 (0.32) | — | |
| SCHEMBL11612997 | 0.60 | ALDH1A1 (0.41) | HSD17B3 | |
| SCHEMBL8180408 | 0.58 | ALDH1A1 (0.33) | — | |
| SCHEMBL3895699 | 0.58 | ALDH1A1 (0.33) | — | |
| SCHEMBL14444946 | 0.56 | KDM4E (0.39) | — | |
| SCHEMBL6714879 | 0.56 | ESR1 (0.32) | — | |
| SCHEMBL10774870 | 0.56 | ESR1 (0.32) | — | |
| SCHEMBL1004507 | 0.55 | MEN1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708413-B2 | Glycosylated linker, compound containing glycosylated linker moiety and physiologically active substance moiety or salt thereof, and methods for producing said compound or salt thereof | GLYTECH, INC. (JP) | 2017-07-18 | — | — | US | disclosed |
| US-9708413-B2 | Glycosylated linker, compound containing glycosylated linker moiety and physiologically active substance moiety or salt thereof, and methods for producing said compound or salt thereof | GLYTECH, INC. (JP) | 2017-07-18 | — | — | US | disclosed |
| US-20150299337-A1 | GLYCOSYLATED LINKER, COMPOUND CONTAINING GLYCOSYLATED LINKER MOIETY AND PHYSIOLOGICALLY ACTIVE SUBSTANCE MOIETY OR SALT THEREOF, AND METHODS FOR PRODUCING SAID U OR SALT THEREOF | GLYTECH INC (JP) | 2015-10-22 | — | — | US | disclosed |
| US-20150299337-A1 | GLYCOSYLATED LINKER, COMPOUND CONTAINING GLYCOSYLATED LINKER MOIETY AND PHYSIOLOGICALLY ACTIVE SUBSTANCE MOIETY OR SALT THEREOF, AND METHODS FOR PRODUCING SAID U OR SALT THEREOF | GLYTECH INC (JP) | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299337-A1 | GLYCOSYLATED LINKER, COMPOUND CONTAINING GLYCOSYLATED LINKER MOIETY AND PHYSIOLOGICALLY ACTIVE SUBSTANCE MOIETY OR SALT THEREOF, AND METHODS FOR PRODUCING SAID U OR SALT THEREOF | CD44, CSGALNACT1, UGGT1 | HSD17B3 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.